Abstract:Introduction: The major challenge to effective oncolytic viral-mediated cancer therapy is the lack of tumor-specific targeting. Myeloid derived suppressor cells (MDSCs) are immature myeloid cells induced by tumor factors which have been shown to migrate to tumors. Better understanding of the kinetics of MDSC migration may enable the use of MDSCs as delivery vectors for tumor-specific therapies. Vesicular Stomatitis Virus (VSV) is an oncolytic rhabdovirus which requires high doses for effective peripherally administered cancer therapy. These doses carry a likelihood of neurotoxic effects in humans. We hypothesize that MDSCs can improve delivery and decrease side effects of VSV therapy. Methods: Ly6C+ monocytic MDSCs were isolated from tumor-bearing BALB/c mice. Cells were stained with Feridex and PKH26 dye and adoptively transferred into BALB/c mice with intrahepatic MCA26 colon cancer. Mice received daily MRI and were sacrificed for FACS, relaxometry, or mass spectrometry. Intrahepatic MCA26 tumor-breaing mice were treated with injection of 5x106 MDSCs cultured with VSV or VSV(M3) virus (MOI:300), with or without α-VSV-G ab and compared for survival to mice receiving PBS, MDSCs alone, free virus, and Ly6c- cells cultured with VSV. Mice were sacrificed and organs harvested for histology and TCID50. Results: We demonstrate via MRI that MDSCs migrate to tumors in an adoptive transfer model of murine hepatic metastases of colon cancer. MDSC levels peak intratumorally 72 hrs after transfer and are identified peripherally and perivasciularly. Intratumoral MDSC levels are elevated compared to spleen (38±2%Injected Dose (%ID) vs 13±0.6%ID, 72hrs, p<0.001), and liver (0.5±1%ID, p<0.001) via mass spectrometry and relaxometry. This is confirmed by FACS, which shows a 7-fold increase of MDSC signaling in the tumor compared to background (p=0.001). We then employ MDSCs as a delivery vehicle for VSV. VSV-infected MDSCs significantly prolong survival in mice with hepatic colon cancer over systemic administration of VSV alone (29.8 days vs 24 days; p<0.0002). Furthermore, the improvement of VSV binding efficiency on MDSCs leads to significantly improved survival when VSV is conjugated to MDSCs using α-VSV-G ab (52.9 days vs 24.9 days; p<0.0001) demonstrating 26% overall survival and no significant toxicity. We confirm increased viral delivery to tumors and decreased delivery to other tissues through histology and TCID50, indicating an improved therapeutic index for VSV therapy when administered via MDSCs. Conclusions: This study demonstrates a proof-of-principle for MDSCs preferentially targeting therapeutics to metastatic tumors. in the future we anticipate that this technique may be applied to a variety of targeted tumor therapies.

Systemic delivery of fusogenic membrane glycoprotein-expressing neural stem cells to selectively kill tumor cells.

Echogenic PEGylated PEI-Loaded Microbubble As Efficient Gene Delivery System.

Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model

Mesenchymal Stem Cells Engineered by Nonviral Vectors: A Powerful Tool in Cancer Gene Therapy

A Novel Role for Myeloid Derived Suppressor Cells in Tumor-specific Therapeutic Targeting

Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration

Therapeutic Efficacy and Fate of Bimodal Engineered Stem Cells in Malignant Brain Tumors

Angiogenesis-targeting Microbubbles Combined with Ultrasound-Mediated Gene Therapy in Brain Tumors

Targeted Nanoparticle‐Mediated Gene Therapy Mimics Oncolytic Virus for Effective Melanoma Treatment

Gene Recombinant Bone Marrow Mesenchymal Stem Cells As a Tumor-Targeted Suicide Gene Delivery Vehicle in Pulmonary Metastasis Therapy Using Non-Viral Transfection.

Synergistic effects of co-administration of suicide gene expressing mesenchymal stem cells and prodrug-encapsulated liposome on aggressive lung melanoma metastases in mice

Glioma Stem Cells Targeted by Oncolytic Virus Carrying Endostatin–angiostatin Fusion Gene and the Expression of Its Exogenous Gene in Vitro

Human Mesenchymal Stem Cells-Like Cells As Cellular Vehicles for Delivery of Immunotoxin in Vitro

Genetically engineered neural stem cells migrate and suppress glioma cell growth at distant intracranial sites.

Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy

Human Bone Marrow Mesenchymal Stem Cells Functionalized by Hybrid Baculovirus-Adeno-Associated Viral Vectors for Targeting Hypopharyngeal Carcinoma

Bystander Effect in Suicide Gene Therapy Using Immortalized Neural Stem Cells Transduced with Herpes Simplex Virus Thymidine Kinase Gene on Medulloblastoma Regression

Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus

Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses

Enhancing the Efficacy of Breast Cancer Immunotherapy Using a Smac-Armed Oncolytic Virus

Noninvasive and Local Delivery of Adenoviral-Mediated Herpes Simplex Virus Thymidine Kinase to Treat Glioma Through Focused Ultrasound-Induced Blood-Brain Barrier Opening in Rats.